Evofem Biosciences, Inc. (EVFM) Form 8-K — May 18, 2026
Evofem Biosciences reported a first-quarter 2026 net loss of $5.5 million, or $0.04 per share, reversing a net income of $1.0 million in the same period last year. The loss was driven by total operating expenses of $5.5 million, which exceeded net sales of $0.9 million, despite a slight year-over-year revenue increase. The company’s balance sheet shows significant financial distress, with a stockholders’ deficit of $77.6 million and only $1.5 million in cash and cash equivalents. Management highlighted 'limited cash resources' and a dependence on new capital or business development transactions to fund ongoing operations.
Key figures
- Revenue
- 899000
- Total Debt
- 78752000
- Revenue Yoy
- 6.3%
- Cash Position
- 1491000
- Operating Expenses
- 5468000
- Weighted Average Shares Basic
- 133246864
Price after filing
Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.